{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T11:36:28Z","timestamp":1786534588126,"version":"build-2736575974"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA214274"],"award-info":[{"award-number":["CA214274"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA276349"],"award-info":[{"award-number":["CA276349"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00411768"],"award-info":[{"award-number":["RS-2024-00411768"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["MCL7001-18"],"award-info":[{"award-number":["MCL7001-18"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Resistance to Bruton\u2019s tyrosine kinase inhibitors (BTKi) remains a major therapeutic challenge in B-cell malignancies. Here, we identify chromatin remodeler BRG1-mediated suppression of ferroptosis as a central mechanism of BTKi resistance in mantle cell lymphoma (MCL), in which aberrant BRG1-dependent transcription program protects cells from BTKi-induced ferroptosis by restricting reactive oxygen species (ROS) and labile iron. Mechanistically, BRG1 promotes resistance through regulation of both BTK-dependent survival signaling and a BTK-independent transcriptional program. The latter is mediated by BRG1-driven induction of MEF2B, which upregulates atypical mitochondrial complex I subunit NDUFA4L2. Increased NDUFA4L2 restricts cellular respiration, preemptively limiting mitochondrial ROS generation and activating AMPK signaling, together reducing susceptibility to lipid peroxidation and ferroptosis. Pharmacologic inhibition of BRG1 disrupts these programs, restoring ferroptotic sensitivity and synergizing with BTKi across resistant MCL models. Together, our study establishes BRG1 as a central regulator of BTKi resistance and provides a rationale for co-targeting BRG1 and BTK as a therapeutic strategy for B-cell malignancies.<\/jats:p>","DOI":"10.1038\/s41467-026-75123-4","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T06:05:35Z","timestamp":1782972335000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["BRG1-mediated suppression of ferroptosis underlies BTK inhibitor resistance"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8548-5777","authenticated-orcid":false,"given":"Soo-Yeon","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1919-4831","authenticated-orcid":false,"given":"Xiangao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helgi","family":"Nikolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7276-278X","authenticated-orcid":false,"given":"Belem","family":"Yoval-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sieun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeongbin","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Gribbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2735-168X","authenticated-orcid":false,"given":"Preetesh","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-5486","authenticated-orcid":false,"given":"Michael","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1151-5427","authenticated-orcid":false,"given":"Lalit","family":"Sehgal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Baiocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inah","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"DiLiberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8469-2283","authenticated-orcid":false,"given":"Alexander","family":"Galkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3932-8946","authenticated-orcid":false,"given":"Hojoong","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lapo","family":"Alinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina","family":"Chen-Kiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9781-7935","authenticated-orcid":false,"given":"Hongwu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5481-2202","authenticated-orcid":false,"given":"Jihye","family":"Paik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"75123_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H. & Jemal, A. Cancer statistics, 2025. CA Cancer J. Clin. 75, 10\u201345 (2025).","journal-title":"CA Cancer J. Clin."},{"key":"75123_CR2","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1182\/blood.2021014162","volume":"139","author":"Y Song","year":"2022","unstructured":"Song, Y. et al. Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood 139, 3148\u20133158 (2022).","journal-title":"Blood"},{"key":"75123_CR3","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1182\/blood.2021013326","volume":"139","author":"TA Eyre","year":"2022","unstructured":"Eyre, T. A., Cheah, C. Y. & Wang, M. L. Therapeutic options for relapsed\/refractory mantle cell lymphoma. Blood 139, 666\u2013677 (2022).","journal-title":"Blood"},{"key":"75123_CR4","first-page":"3137","volume":"141","author":"PA Thompson","year":"2023","unstructured":"Thompson, P. A. & Tam, C. S. Pirtobrutinib: a new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders. Blood 141, 3137\u20133142 (2023).","journal-title":"Blood"},{"key":"75123_CR5","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.1200\/JCO.23.00775","volume":"41","author":"PL Zinzani","year":"2023","unstructured":"Zinzani, P. L. et al. ROSEWOOD: a phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma. J. Clin. Oncol. 41, 5107\u20135117 (2023).","journal-title":"J. Clin. Oncol."},{"key":"75123_CR6","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1182\/bloodadvances.2022009389","volume":"7","author":"PWM Johnson","year":"2023","unstructured":"Johnson, P. W. M. et al. Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial. Blood Adv. 7, 2008\u20132017 (2023).","journal-title":"Blood Adv."},{"key":"75123_CR7","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","volume":"127","author":"P Martin","year":"2016","unstructured":"Martin, P. et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood 127, 1559\u20131563 (2016).","journal-title":"Blood"},{"key":"75123_CR8","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1038\/s41375-019-0575-9","volume":"33","author":"M Wang","year":"2019","unstructured":"Wang, M. et al. Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. Leukemia 33, 2762\u20132766 (2019).","journal-title":"Leukemia"},{"key":"75123_CR9","doi-asserted-by":"publisher","first-page":"4216","DOI":"10.1158\/1078-0432.CCR-19-3703","volume":"26","author":"Y Song","year":"2020","unstructured":"Song, Y. et al. Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of Bruton\u2019s tyrosine kinase. Clin. Cancer Res. 26, 4216\u20134224 (2020).","journal-title":"Clin. Cancer Res."},{"key":"75123_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0209-5","volume":"9","author":"A Kumar","year":"2019","unstructured":"Kumar, A. et al. Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse. Blood Cancer J. 9, 50 (2019).","journal-title":"Blood Cancer J."},{"key":"75123_CR11","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1182\/blood.2020006783","volume":"138","author":"DM Stephens","year":"2021","unstructured":"Stephens, D. M. & Byrd, J. C. Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies. Blood 138, 1099\u20131109 (2021).","journal-title":"Blood"},{"key":"75123_CR12","doi-asserted-by":"crossref","unstructured":"Zhang, L. et al. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Sci Transl. Med. 11, eaau1167 (2019).","DOI":"10.1126\/scitranslmed.aau1167"},{"key":"75123_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2023.2264430","volume":"65","author":"C Gribbin","year":"2024","unstructured":"Gribbin, C., Chen, J., Martin, P. & Ruan, J. Novel treatment for mantle cell lymphoma\u2014impact of BTK inhibitors and beyond. Leuk. Lymphoma 65, 1\u201313 (2024).","journal-title":"Leuk. Lymphoma"},{"key":"75123_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2026.101383","volume":"86","author":"S Yang","year":"2026","unstructured":"Yang, S., Oh, J., Hwang, S. Y., Paik, J. & Hwang, I. Advances and resistance adaptation in BTK-targeted therapy for B-cell malignancies. Drug Resist. Updates 86, 101383 (2026).","journal-title":"Drug Resist. Updates"},{"key":"75123_CR15","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon, S. J. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060\u20131072 (2012).","journal-title":"Cell"},{"key":"75123_CR16","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang, X., Stockwell, B. R. & Conrad, M. Ferroptosis: mechanisms, biology and role in disease. Nat. Rev. Mol. Cell Biol. 22, 266\u2013282 (2021).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"75123_CR17","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.tcb.2020.02.009","volume":"30","author":"BR Stockwell","year":"2020","unstructured":"Stockwell, B. R., Jiang, X. & Gu, W. Emerging mechanisms and disease relevance of ferroptosis. Trends Cell Biol. 30, 478\u2013490 (2020).","journal-title":"Trends Cell Biol."},{"key":"75123_CR18","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1158\/1541-7786.MCR-18-0256","volume":"17","author":"SC Lee","year":"2019","unstructured":"Lee, S. C. et al. Metabolic detection of Bruton\u2019s tyrosine kinase inhibition in mantle cell lymphoma cells. Mol. Cancer Res. 17, 1365\u20131377 (2019).","journal-title":"Mol. Cancer Res."},{"key":"75123_CR19","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/s41571-019-0190-8","volume":"16","author":"D Sermer","year":"2019","unstructured":"Sermer, D., Pasqualucci, L., Wendel, H. G., Melnick, A. & Younes, A. Emerging epigenetic-modulating therapies in lymphoma. Nat. Rev. Clin. Oncol. 16, 494\u2013507 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"75123_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.108870","volume":"34","author":"X Zhao","year":"2021","unstructured":"Zhao, X. et al. Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma. Cell Rep. 34, 108870 (2021).","journal-title":"Cell Rep."},{"key":"75123_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14920","volume":"8","author":"X Zhao","year":"2017","unstructured":"Zhao, X. et al. Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nat. Commun. 8, 14920 (2017).","journal-title":"Nat. Commun."},{"key":"75123_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01736-8","volume":"22","author":"A Andrades","year":"2023","unstructured":"Andrades, A. et al. SWI\/SNF complexes in hematological malignancies: biological implications and therapeutic opportunities. Mol. Cancer 22, 39 (2023).","journal-title":"Mol. Cancer"},{"key":"75123_CR23","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.cell.2018.09.032","volume":"175","author":"N Mashtalir","year":"2018","unstructured":"Mashtalir, N. et al. Modular organization and assembly of SWI\/SNF family chromatin remodeling complexes. Cell 175, 1272\u20131288.e1220 (2018).","journal-title":"Cell"},{"key":"75123_CR24","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/s41591-018-0019-5","volume":"24","author":"Y Lissanu Deribe","year":"2018","unstructured":"Lissanu Deribe, Y. et al. Mutations in the SWI\/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer. Nat. Med. 24, 1047\u20131057 (2018).","journal-title":"Nat. Med."},{"key":"75123_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7580","volume":"6","author":"K Tan","year":"2015","unstructured":"Tan, K. et al. Mitochondrial SSBP1 protects cells from proteotoxic stresses by potentiating stress-induced HSF1 transcriptional activity. Nat. Commun. 6, 6580 (2015).","journal-title":"Nat. Commun."},{"key":"75123_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114345","volume":"43","author":"KP Bhat","year":"2024","unstructured":"Bhat, K. P. et al. CRISPR activation screens identify the SWI\/SNF ATPases as suppressors of ferroptosis. Cell Rep. 43, 114345 (2024).","journal-title":"Cell Rep."},{"key":"75123_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19402-8","volume":"11","author":"TM Fernando","year":"2020","unstructured":"Fernando, T. M. et al. Functional characterization of SMARCA4 variants identified by targeted exome-sequencing of 131,668 cancer patients. Nat. Commun. 11, 5551 (2020).","journal-title":"Nat. Commun."},{"key":"75123_CR28","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/path.4633","volume":"238","author":"AN Karnezis","year":"2016","unstructured":"Karnezis, A. N. et al. Dual loss of the SWI\/SNF complex ATPases SMARCA4\/BRG1 and SMARCA2\/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type. J. Pathol. 238, 389\u2013400 (2016).","journal-title":"J. Pathol."},{"key":"75123_CR29","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1158\/1535-7163.MCT-21-0433","volume":"20","author":"K Mardinian","year":"2021","unstructured":"Mardinian, K., Adashek, J. J., Botta, G. P., Kato, S. & Kurzrock, R. SMARCA4: implications of an altered chromatin-remodeling gene for cancer development and therapy. Mol. Cancer Ther. 20, 2341\u20132351 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"75123_CR30","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1101\/gad.232710.113","volume":"27","author":"J Shi","year":"2013","unstructured":"Shi, J. et al. Role of SWI\/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation. Genes Dev. 27, 2648\u20132662 (2013).","journal-title":"Genes Dev."},{"key":"75123_CR31","doi-asserted-by":"crossref","unstructured":"Xiao, L. et al. Targeting SWI\/SNF ATPases in enhancer-addicted prostate cancer. Nature 601, 434\u2013439 (2022).","DOI":"10.1038\/s41586-021-04246-z"},{"key":"75123_CR32","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41571-020-0357-3","volume":"17","author":"P Mittal","year":"2020","unstructured":"Mittal, P. & Roberts, C. W. M. The SWI\/SNF complex in cancer\u2014biology, biomarkers and therapy. Nat. Rev. Clin. Oncol. 17, 435\u2013448 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"75123_CR33","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ccell.2024.02.011","volume":"42","author":"Q Deng","year":"2024","unstructured":"Deng, Q. et al. SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions. Cancer Cell 42, 605\u2013622.e611 (2024).","journal-title":"Cancer Cell"},{"key":"75123_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.89","volume":"5","author":"MA Lunning","year":"2015","unstructured":"Lunning, M. A. & Green, M. R. Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas. Blood Cancer J. 5, e361 (2015).","journal-title":"Blood Cancer J."},{"key":"75123_CR35","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nature11378","volume":"490","author":"R Schmitz","year":"2012","unstructured":"Schmitz, R. et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 490, 116\u2013120 (2012).","journal-title":"Nature"},{"key":"75123_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01333-6","volume":"15","author":"A De Bol\u00f2s","year":"2025","unstructured":"De Bol\u00f2s, A. et al. The SOX11:SMARCA4 complex is a driver of oncogenic transcriptional programs in mantle cell lymphoma. Blood Cancer J. 15, 127 (2025).","journal-title":"Blood Cancer J."},{"key":"75123_CR37","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","volume":"25","author":"R Agarwal","year":"2019","unstructured":"Agarwal, R. et al. Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. Nat. Med. 25, 119\u2013129 (2019).","journal-title":"Nat. Med."},{"key":"75123_CR38","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","volume":"378","author":"CS Tam","year":"2018","unstructured":"Tam, C. S. et al. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma. N. Engl. J. Med. 378, 1211\u20131223 (2018).","journal-title":"N. Engl. J. Med."},{"key":"75123_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00927-2","volume":"13","author":"P Jain","year":"2023","unstructured":"Jain, P. et al. Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma. Blood Cancer J. 13, 156 (2023).","journal-title":"Blood Cancer J."},{"key":"75123_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37480-2","volume":"14","author":"F Li","year":"2023","unstructured":"Li, F. et al. Histone demethylase KDM2A is a selective vulnerability of cancers relying on alternative telomere maintenance. Nat. Commun. 14, 1756 (2023).","journal-title":"Nat. Commun."},{"key":"75123_CR41","doi-asserted-by":"crossref","unstructured":"Jang, J. Y. et al. A FOXO1-dependent transcription network is a targetable vulnerability of mantle cell lymphomas. J. Clin. Investig. 132, e160767 (2022).","DOI":"10.1172\/JCI160767"},{"key":"75123_CR42","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/S1074-7613(00)80040-0","volume":"10","author":"LA Garrett-Sinha","year":"1999","unstructured":"Garrett-Sinha, L. A. et al. PU.1 and Spi-B are required for normal B cell receptor-mediated signal transduction. Immunity 10, 399\u2013408 (1999).","journal-title":"Immunity"},{"key":"75123_CR43","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.ccell.2024.02.010","volume":"42","author":"D Barisic","year":"2024","unstructured":"Barisic, D. et al. ARID1A orchestrates SWI\/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis. Cancer Cell 42, 583\u2013604.e11 (2024).","journal-title":"Cancer Cell"},{"key":"75123_CR44","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.ccell.2018.08.006","volume":"34","author":"P Brescia","year":"2018","unstructured":"Brescia, P. et al. MEF2B instructs germinal center development and acts as an oncogene in B cell lymphomagenesis. Cancer Cell 34, 453\u2013465 e459 (2018).","journal-title":"Cancer Cell"},{"key":"75123_CR45","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3109\/03602532.2011.558092","volume":"43","author":"LM Balogh","year":"2011","unstructured":"Balogh, L. M. & Atkins, W. M. Interactions of glutathione transferases with 4-hydroxynonenal. Drug Metab. Rev. 43, 165\u2013178 (2011).","journal-title":"Drug Metab. Rev."},{"key":"75123_CR46","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41416-019-0660-x","volume":"122","author":"N Liu","year":"2020","unstructured":"Liu, N., Lin, X. & Huang, C. Activation of the reverse transsulfuration pathway through NRF2\/CBS confers erastin-induced ferroptosis resistance. Br. J. Cancer 122, 279\u2013292 (2020).","journal-title":"Br. J. Cancer"},{"key":"75123_CR47","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2118646119","volume":"119","author":"GC Forcina","year":"2022","unstructured":"Forcina, G. C. et al. Ferroptosis regulation by the NGLY1\/NFE2L1 pathway. Proc. Natl. Acad. Sci. USA 119, e2118646119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"75123_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217992","volume":"633","author":"C Xia","year":"2025","unstructured":"Xia, C. et al. Synergistic targeting of FASN and HMGCS1 by cerulenin enhances tumor cell ferroptosis sensitivity through rewiring lipid metabolism and blocking GPX4 biosynthesis. Cancer Lett. 633, 217992 (2025).","journal-title":"Cancer Lett."},{"key":"75123_CR49","doi-asserted-by":"publisher","unstructured":"Arner, E. N. et al. Impaired oxidative phosphorylation drives primary tumor escape and metastasis. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.01.08.631936 (2025).","DOI":"10.1101\/2025.01.08.631936"},{"key":"75123_CR50","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.cmet.2011.10.008","volume":"14","author":"D Tello","year":"2011","unstructured":"Tello, D. et al. Induction of the mitochondrial NDUFA4L2 protein by HIF-1alpha decreases oxygen consumption by inhibiting Complex I activity. Cell Metab. 14, 768\u2013779 (2011).","journal-title":"Cell Metab."},{"key":"75123_CR51","doi-asserted-by":"crossref","unstructured":"Chen, X., Yu, C., Kang, R. & Tang, D. Iron metabolism in ferroptosis. Front. Cell Dev. Biol. 8, 590226 (2020).","DOI":"10.3389\/fcell.2020.590226"},{"key":"75123_CR52","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.1128\/MCB.17.5.2876","volume":"17","author":"AG West","year":"1997","unstructured":"West, A. G., Shore, P. & Sharrocks, A. D. DNA binding by MADS-box transcription factors: a molecular mechanism for differential DNA bending. Mol. Cell. Biol. 17, 2876\u20132887 (1997).","journal-title":"Mol. Cell. Biol."},{"key":"75123_CR53","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nature14893","volume":"524","author":"M Lazarou","year":"2015","unstructured":"Lazarou, M. et al. The ubiquitin kinase PINK1 recruits autophagy receptors to induce mitophagy. Nature 524, 309\u2013314 (2015).","journal-title":"Nature"},{"key":"75123_CR54","doi-asserted-by":"crossref","unstructured":"Lins, F. V. et al. Ibrutinib modulates proliferation, migration, mitochondrial homeostasis, and apoptosis in melanoma cells. Biomedicines 12, 1012 (2024).","DOI":"10.3390\/biomedicines12051012"},{"key":"75123_CR55","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00401-022-02411-w","volume":"143","author":"R Li","year":"2022","unstructured":"Li, R. et al. BTK inhibition limits B-cell-T-cell interaction through modulation of B-cell metabolism: implications for multiple sclerosis therapy. Acta Neuropathol. 143, 505\u2013521 (2022).","journal-title":"Acta Neuropathol."},{"key":"75123_CR56","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.molcel.2018.10.042","volume":"73","author":"M Gao","year":"2019","unstructured":"Gao, M. et al. Role of mitochondria in ferroptosis. Mol. Cell 73, 354\u2013363 e353 (2019).","journal-title":"Mol. Cell"},{"key":"75123_CR57","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/s41419-019-2064-5","volume":"10","author":"E Park","year":"2019","unstructured":"Park, E. & Chung, S. W. ROS-mediated autophagy increases intracellular iron levels and ferroptosis by ferritin and transferrin receptor regulation. Cell Death Dis. 10, 822 (2019).","journal-title":"Cell Death Dis."},{"key":"75123_CR58","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41556-020-0461-8","volume":"22","author":"H Lee","year":"2020","unstructured":"Lee, H. et al. Energy-stress-mediated AMPK activation inhibits ferroptosis. Nat. Cell Biol. 22, 225\u2013234 (2020).","journal-title":"Nat. Cell Biol."},{"key":"75123_CR59","doi-asserted-by":"publisher","first-page":"4284","DOI":"10.1182\/blood-2023-178090","volume":"142","author":"CD DiNardo","year":"2023","unstructured":"DiNardo, C. D. et al. Preliminary results from a phase 1 dose escalation study of FHD-286, a novel BRG1\/BRM (SMARCA4\/SMARCA2) inhibitor, administered as an oral monotherapy in patients with advanced hematologic malignancies. Blood 142, 4284\u20134284 (2023).","journal-title":"Blood"},{"key":"75123_CR60","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood-2023-183029","volume":"142","author":"EB Gomez","year":"2023","unstructured":"Gomez, E. B. et al. Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor. Blood 142, 62\u201372 (2023).","journal-title":"Blood"},{"key":"75123_CR61","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1158\/0008-5472.CAN-06-1962","volume":"67","author":"Y Lepelletier","year":"2007","unstructured":"Lepelletier, Y. et al. Prevention of mantle lymphoma tumor establishment by routing transferrin receptor toward lysosomal compartments. Cancer Res. 67, 1145\u20131154 (2007).","journal-title":"Cancer Res."},{"key":"75123_CR62","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/s41586-025-08974-4","volume":"642","author":"T Ca\u00f1eque","year":"2025","unstructured":"Ca\u00f1eque, T. et al. Activation of lysosomal iron triggers ferroptosis in cancer. Nature 642, 492\u2013500 (2025).","journal-title":"Nature"},{"key":"75123_CR63","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.7150\/thno.101821","volume":"15","author":"S Ovejero","year":"2025","unstructured":"Ovejero, S. et al. Ironomycin induces mantle cell lymphoma cell death by targeting iron metabolism addiction. Theranostics 15, 2834\u20132851 (2025).","journal-title":"Theranostics"},{"key":"75123_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175526","volume":"943","author":"SA Setiawan","year":"2023","unstructured":"Setiawan, S. A. et al. Synergistic disruption of BTK and BCL-2 causes apoptosis while inducing ferroptosis in double-hit lymphoma. Eur. J. Pharmacol. 943, 175526 (2023).","journal-title":"Eur. J. Pharmacol."},{"key":"75123_CR65","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41420-025-02826-w","volume":"11","author":"A Langpape","year":"2025","unstructured":"Langpape, A. et al. Redox destabilization by ibrutinib promotes ferroptosis in diffuse large B-cell lymphoma (DLBCL). Cell Death Discov. 11, 495 (2025).","journal-title":"Cell Death Discov."},{"key":"75123_CR66","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/ni.2688","volume":"14","author":"CY Ying","year":"2013","unstructured":"Ying, C. Y. et al. MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma. Nat. Immunol. 14, 1084\u20131092 (2013).","journal-title":"Nat. Immunol."},{"key":"75123_CR67","doi-asserted-by":"publisher","first-page":"18250","DOI":"10.1073\/pnas.1314608110","volume":"110","author":"S Bea","year":"2013","unstructured":"Bea, S. et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc. Natl. Acad. Sci. USA 110, 18250\u201318255 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"75123_CR68","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1080\/10428194.2021.1933480","volume":"62","author":"JM Rodrigues","year":"2021","unstructured":"Rodrigues, J. M., Porwit, A., Hassan, M., Ek, S. & Jerkeman, M. Targeted genomic investigations in a population-based cohort of mantle cell lymphoma reveal novel clinically relevant targets. Leuk. Lymphoma 62, 2637\u20132647 (2021).","journal-title":"Leuk. Lymphoma"},{"key":"75123_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101484","volume":"5","author":"N-M Hoang","year":"2024","unstructured":"Hoang, N.-M. et al. Targeting DNMT3A-mediated oxidative phosphorylation to overcome ibrutinib resistance in mantle cell lymphoma. Cell Rep. Med. 5, 101484 (2024).","journal-title":"Cell Rep. Med."},{"key":"75123_CR70","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/s41586-023-06409-6","volume":"620","author":"LM Sanmarco","year":"2023","unstructured":"Sanmarco, L. M. et al. Lactate limits CNS autoimmunity by stabilizing HIF-1alpha in dendritic cells. Nature 620, 881\u2013889 (2023).","journal-title":"Nature"},{"key":"75123_CR71","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-20-4842","volume":"27","author":"MS Davids","year":"2021","unstructured":"Davids, M. S. et al. Long-term follow-up of patients with relapsed or refractory non-Hodgkin lymphoma treated with Venetoclax in a phase I, first-in-human study. Clin. Cancer Res. 27, 4690\u20134695 (2021).","journal-title":"Clin. Cancer Res."},{"key":"75123_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13989-3","volume":"11","author":"C Ballabio","year":"2020","unstructured":"Ballabio, C. et al. Modeling medulloblastoma in vivo and with human cerebellar organoids. Nat. Commun. 11, 583 (2020).","journal-title":"Nat. Commun."},{"key":"75123_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20839-0","volume":"12","author":"I Hwang","year":"2021","unstructured":"Hwang, I. et al. Cellular stress signaling activates type-I IFN response through FOXO3-regulated lamin posttranslational modification. Nat. Commun. 12, 640 (2021).","journal-title":"Nat. Commun."},{"key":"75123_CR74","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1097\/PAI.0000000000000370","volume":"25","author":"SM Seyed Jafari","year":"2017","unstructured":"Seyed Jafari, S. M. & Hunger, R. E. IHC optical density score: a new practical method for quantitative immunohistochemistry image analysis. Appl. Immunohistochem. Mol. Morphol. 25, e12\u2013e13 (2017).","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"75123_CR75","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1038\/s41596-022-00692-9","volume":"17","author":"FC Grandi","year":"2022","unstructured":"Grandi, F. C., Modi, H., Kampman, L. & Corces, M. R. Chromatin accessibility profiling by ATAC-seq. Nat. Protoc. 17, 1518\u20131552 (2022).","journal-title":"Nat. Protoc."},{"key":"75123_CR76","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"75123_CR77","doi-asserted-by":"publisher","first-page":"D571","DOI":"10.1093\/nar\/gkac935","volume":"51","author":"N Zhou","year":"2023","unstructured":"Zhou, N. et al. FerrDb V2: update of the manually curated database of ferroptosis regulators and ferroptosis-disease associations. Nucleic Acids Res. 51, D571\u2013d582 (2023).","journal-title":"Nucleic Acids Res."},{"key":"75123_CR78","doi-asserted-by":"publisher","first-page":"W216","DOI":"10.1093\/nar\/gkac194","volume":"50","author":"BT Sherman","year":"2022","unstructured":"Sherman, B. T. et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 50, W216\u2013w221 (2022).","journal-title":"Nucleic Acids Res."},{"key":"75123_CR79","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1182\/blood-2018-11-886457","volume":"133","author":"P Martin","year":"2019","unstructured":"Martin, P. et al. A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. Blood 133, 1201\u20131204 (2019).","journal-title":"Blood"},{"key":"75123_CR80","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1182\/blood-2024-209415","volume":"144","author":"M Di Liberto","year":"2024","unstructured":"Di Liberto, M. et al. Disrupting IL10 signaling overcomes compound copy number variation-driven clinical resistance to CDK4\/6 and BTK inhibition in mantle cell lymphoma. Blood 144, 831\u2013832 (2024).","journal-title":"Blood"},{"key":"75123_CR81","doi-asserted-by":"crossref","unstructured":"Korsunsky, I. et al. Fast, sensitive, and flexible integration of single cell data with Harmony. Nat. Methods 16, 1289\u20131296 (2019).","DOI":"10.1038\/s41592-019-0619-0"},{"key":"75123_CR82","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888\u20131902.e21 (2019).","journal-title":"Cell"},{"key":"75123_CR83","first-page":"2579","volume":"9","author":"VD Maaten","year":"2008","unstructured":"Maaten, V. D. & Hinton, G. Visualizing data using t-SNE. J. Mach. Learn. Res. 9, 2579\u20132605 (2008).","journal-title":"J. Mach. Learn. Res."},{"key":"75123_CR84","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41590-018-0276-y","volume":"20","author":"D Aran","year":"2019","unstructured":"Aran, D. et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat. Immunol. 20, 163\u2013172 (2019).","journal-title":"Nat. Immunol."},{"key":"75123_CR85","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.cell.2016.11.007","volume":"167","author":"HG Stunnenberg","year":"2016","unstructured":"Stunnenberg, H. G. & Hirst, M.International Human Epigenome Consortium The International Human Epigenome Consortium: a blueprint for scientific collaboration and discovery. Cell 167, 1145\u20131149 (2016).","journal-title":"Cell"},{"key":"75123_CR86","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1182\/blood-2024-209415","volume":"144","author":"M Di Liberto","year":"2024","unstructured":"Di Liberto, M. et al. Disrupting IL10 signaling overcomes compound copy number variation-driven clinical resistance to CDK4\/6 and BTK inhibition in mantle cell lymphoma. Blood 144, 831\u2013831 (2024).","journal-title":"Blood"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75123-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75123-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75123-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T11:02:48Z","timestamp":1786532568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75123-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":86,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["75123"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-75123-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"26 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.A.B. received research support from Prelude Therapeutics and is on the SAB for Sobi, Pierre Fabre, and Atara Therapeutics. L.S. is a consultant for the Institute for Follicular Lymphoma Innovation. P.M. consulted for AstraZeneca, BeOne, Roche-Genentech, and Pepromene. C.G. consulted for Ipsen and Kite. M.W. reports consultancy for AstraZeneca, BeOne, Galapagos NV, InnoCare, Kite Pharma, Pepromene Bio; research funding from AbbVie, AstraZeneca, Bantam Pharma, BeOne, Eli Lilly, Genentech, Genmab, Incyte, InnoCare, Janssen, Juno, Kite, Loxo, Nurix, Oncternal, Pharmacyclics, Velosbio; and honoraria from AstraZeneca, BeOne, CAHON, Hospital Sirio Libanes, Kite, LRF, MD Education, MJH Life Sciences, OncLive, Ottawa Hospital, Scientific Education Support, Scripps, SOHO Asia, UPMC. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"8220"}}